ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0531

Development and Performance of a Diagnostic Precision Biomarker for Seronegative Rheumatoid Arthritis Based on DNA Methylation in Blood

Espen Riskedal1, Karl Trygve Kalleberg1, Arne Søraas2, Maria Dahl Mjaavatten3, Grethe-Elisabeth Stenvik4, Joe Sexton4, Janis Neumann1, Cathrine Lund Hadley1, Guro Goll4, Silje Watterdal Syversen4, Håkon Bøås5, Jennifer Ruth Harris5, Astanand Jugessur5, Siri Lillegraven4 and Espen Haavardsholm4, 1Age Labs AS, Oslo, Oslo, Norway, 2Age Labs AS, Eiksmarka, Norway, 3Diakonhjemmet Hospital, Haslum, Norway, 4Diakonhjemmet Hospital, Oslo, Norway, 5Norwegian Institute of Public Health, Oslo, Norway

Meeting: ACR Convergence 2022

Keywords: Biomarkers, Epigenetics, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Abstracts: RA – Diagnosis, Manifestations, and Outcomes I: Pre- and Early Disease

Session Type: Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Patients with seronegative rheumatoid arthritis (RA) exhibit no detectable antibodies, often resulting in delayed diagnosis and treatment initiation. A blood-based test, capable of detecting seronegative RA earlier in the disease course, would address a significant unmet clinical need. It has previously been demonstrated that epigenetic changes in general, and DNA methylation (DNAm) changes in particular, are strongly associated with several autoimmune diseases, including RA. The aim of the project was to train and validate a novel DNAm-based classification algorithm that identifies RA, in particular seronegative RA.

Methods: We compiled whole-blood DNAm profiles from i) 354 treatment-naïve seropositive RA patients, ii) 335 healthy controls, and iii) 485 patients diagnosed with other autoimmune diseases into a discovery dataset (Fig. 1). Feature extraction was conducted to identify methylation markers specifically suited to distinguish between RA and non-RA in the discovery dataset (Fig. 1).

A modeling dataset was constructed from whole-blood DNAm profiles obtained from i) 94 treatment-naïve seropositive RA (n=58) and seronegative RA (n=36) patients, ii) 74 patients with arthritic diseases such as reactive arthritis, psoriatic arthritis and unspecified arthritis, and iii) 50 healthy controls (Fig. 1). The dataset was split into two subsets: a training set (80%) and a separate holdout set (20%), used only for scoring performance. The subsets were stratified to ensure a balanced distribution of diagnoses, age and sex.

A binary classification algorithm was developed in the training set, using the methylation markers identified in the discovery dataset, age, sex and serology results as potential predictors. The outcome variable was the final diagnosis made by the rheumatologist. Seronegative and seropositive RA were coded as cases, whereas all other arthritides and healthy controls were coded as controls (Fig. 1). The best performing algorithm was validated and scored in the holdout set (Fig. 1).

Results: In the holdout set of 46 samples, comprising 13 seropositive RA, 8 seronegative RA, 14 other arthritis, and 11 healthy controls, the binary classifier showed an AUC of 0.96, a sensitivity of 0.90, a specificity of 0.88, and an accuracy of 0.89 for classification of RA overall (Fig. 2). In the two RA subgroups, the classifier showed an accuracy of 0.75 for seronegative disease, while seropositive disease was classified with an accuracy of 1.0 (Fig. 3). Patients with other arthritides were classified as “non-RA”, with an accuracy of 1.0 for reactive arthritis, an accuracy of 0.83 for unspecified arthritis, and an accuracy of 0.5 for psoriatic arthritis (Fig. 3). Healthy controls were classified as non-RA with an accuracy of 1.0 (Fig. 3).

Conclusion: We report on the development of a novel precision biomarker that is able to accurately discriminate seronegative and seropositive RA from other arthritides and healthy controls. We propose that this precision biomarker may, after further validation, serve as a new tool for diagnosing RA, and be of special importance for early identification of seronegative RA patients.

Supporting image 1

Fig 1. Flowchart of algorithm development process

Supporting image 2

Fig 2. AUC of algorithm in holdout set and training set

Supporting image 3

Fig 3. Scatter plot of classification results in holdout set


Disclosures: E. Riskedal, Age Labs AS; K. Kalleberg, Age Labs AS; A. Søraas, Age Labs AS; M. Mjaavatten, None; G. Stenvik, None; J. Sexton, None; J. Neumann, Age Labs AS; C. Hadley, Age Labs; G. Goll, Galapagos, Abbvie, UCB, Fizer; S. Syversen, None; H. Bøås, None; J. Harris, None; A. Jugessur, None; S. Lillegraven, None; E. Haavardsholm, Pfizer, AbbVie, Eli Lilly, UCB, Boehringer-Ingelheim, Gilead.

To cite this abstract in AMA style:

Riskedal E, Kalleberg K, Søraas A, Mjaavatten M, Stenvik G, Sexton J, Neumann J, Hadley C, Goll G, Syversen S, Bøås H, Harris J, Jugessur A, Lillegraven S, Haavardsholm E. Development and Performance of a Diagnostic Precision Biomarker for Seronegative Rheumatoid Arthritis Based on DNA Methylation in Blood [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/development-and-performance-of-a-diagnostic-precision-biomarker-for-seronegative-rheumatoid-arthritis-based-on-dna-methylation-in-blood/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-and-performance-of-a-diagnostic-precision-biomarker-for-seronegative-rheumatoid-arthritis-based-on-dna-methylation-in-blood/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology